Current challenges in islet transplantation

Current Diabetes Reports

Volumn 8, Issue 4, 2008, Pages 324-331

  Leitão, Cristiane B ^b   Cure, Pablo ^b   Tharavanij, Thipaporn ^b   Baidal, David A ^b   Alejandro, Rodolfo ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; C PEPTIDE; COLLAGENASE; COTRIMOXAZOLE; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ETANERCEPT; EXENDIN 4; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN DERIVATIVE; IRON; LIBERASE HI; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR; GLYCOSYLATED HEMOGLOBIN;

ACNE; ALBUMINURIA; ANEMIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CELL ISOLATION; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIARRHEA; DONOR SELECTION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECZEMA; FOLLICULITIS; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GONADAL DISEASE; GOOD MANUFACTURING PRACTICE; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY DISEASE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; METABOLIC DISORDER; MONOTHERAPY; MOUTH ULCER; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OVARY CYST; PAIN; PANCREAS ISLET TRANSPLANTATION; PARESTHESIA; PNEUMOCYSTOSIS; PROTEINURIA; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREMOR; ALLOTRANSPLANTATION; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; METHODOLOGY; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; QUALITY OF LIFE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 52649127411     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0057-3     Document Type: Review

References (50)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
2. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [no authors listed]. Diabetes 1997, 46:271-286.
3. Gruessner RW, Sutherland DE, Kandaswamy R, Gruessner AC: Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. Transplantation 2009, 85:42-47.
4. Robertson RP: Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med 2004, 350:694-705.
5. Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230-238.
6. Shapiro AM, Ricordi C, Hering BJ, et al.: International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355:1318-1330.
7. Ryan EA, Paty BW, Senior PA, et al.: Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
8. Froud T, Ricordi C, Baidal DA, et al.: Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005, 5:2037-2046.
9. Poggioli R, Faradji RN, Ponte G, et al.: Quality of life after islet transplantation. Am J Transplant 2006, 6:371-378.
10. Wonnacott K: Update on regulatory issues in pancreatic islet transplantation. Am J Ther 2005, 12:600-604.
11. Stegall MD, Dean PG, Sung R, et al.: The rationale for the new deceased donor pancreas allocation schema. Transplantation 2007, 83:1156-1161.
12. Shapiro AM, Sutherland DE: The new deceased donor pancreas allocation schema: do the recommendations go far enough? Transplantation 2007, 83:1151-1152.
13. Ponte GM, Pileggi A, Messinger S, et al.: Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant 2007, 16:595-607.
14. Lakey JR, Warnock GL, Rajotte RV, et al.: Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 1996, 61:1047-1053.
15. Caballero-Corbalan J, Eich T, Lundgren T, et al.: No beneficial effect of two-layer storage compared with UW-storage on human islet isolation and transplantation. Transplantation 2007, 84:864-869.
16. Ricordi C, Fraker C, Szust J, et al.: Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation 2003, 75:1524-1527.
17. Ricordi C, Lacy PE, Scharp DW: Automated islet isolation from human pancreas. Diabetes 1989, 38(Suppl 1):140-142.
18. Ichii H, Pileggi A, Molano RD, et al.: Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005, 5:21-30.
19. Ichii H, Sakuma Y, Pileggi A, et al.: Shipment of human islets for transplantation. Am J Transplant 2007, 7:1010-1020.
20. Goss JA, Soltes G, Goodpastor SE, et al.: Pancreatic islet transplantation: the radiographic approach. Transplantation 2003, 76:199-203.
21. Baidal DA, Froud T, Ferreira JV, et al.: The bag method for islet cell infusion. Cell Transplant 2003, 12:809-813.
22. Barshes NR, Lee TC, Goodpastor SE, et al.: Transaminitis after pancreatic islet transplantation. J Am Coll Surg 2005, 200:353-361.
23. Collaborative Islet Transplant Registry (CITR). Available at http://www.citregistry.org/. Accessed February 2008.
24. Faradji RN, Monroy K, Messinger S, et al.: Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007, 7:303-308.
25. Ryan EA, Paty BW, Senior PA, et al.: Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care 2005, 28:343-347.
26. Faradji RN, Monroy K, Riefkohl A, et al.: Continuous glucose monitoring system for early detection of graft dysfunction in allogenic islet transplant recipients. Transplant Proc 2006, 38:3274-3276.
27. Hafiz MM, Faradji RN, Froud T, et al.: Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005, 80:1718-1728.
28. Cure P, Pileggi A, Faradji RN, et al.: Cytomegalovirus infection in a recipient of solitary allogeneic islets. Am J Transplant 2006, 6(5 Pt 1):1089-1090.
29. Maffi P, Angeli E, Bertuzzi F, et al.: Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant 2005, 14:727-733.
30. Bhargava R, Senior PA, Ackerman TE, et al.: Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004, 53:1311-1317.
31. Markmann JF, Rosen M, Siegelman ES, et al.: Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003, 52:1591-1594.
32. Rafael E, Tibell A, Ryden M, et al.: Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transplant 2008, 8:458-462.
33. Larsen JL, Bennett RG, Burkman T, et al.: Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats. Transplantation 2006, 82:466-470.
34. Wyzgal J, Paczek L, Sanko-Resmer J, et al.: Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. Ann Transplant 2007, 12:26-29.
35. Bell E, Cao X, Moibi JA, et al.: Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003, 52:2731-2739.
36. Zhang N, Su D, Qu S, et al.: Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006, 55:2429-2436.
37. Zahr E, Molano RD, Pileggi A, et al.: Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007, 84:1576-1583.
38. Krebs M, Brunmair B, Brehm A, et al.: The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007, 56:1600-1607.
39. Paty BW, Harmon JS, Marsh CL, Robertson RP: Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002, 73:353-357.
40. Havrdova T, Saudek F, Boucek P, et al.: Metabolic effect of sirolimus versus mycophenolate mofetil on pancreatic graft function in the early posttransplant period. Transplant Proc 2005, 37:3544-3545.
41. Han D, Xu X, Baidal D, et al.: Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004, 53:2281-2290.
42. Hering BJ, Kandaswamy R, Ansite JD, et al.: Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005, 293:830-835.
43. Fung MA, Warnock GL, Ao Z, et al.: The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation 2007, 84:17-22.
44. Gillard P, Ling Z, Mathieu C, et al.: Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 2008, 85:256-263.
45. Kawai T, Cosimi AB, Spitzer TR, et al.: HLA-mismatched renal transplantation without maintenance immunosuppression. N EnglJ Med 2008, 358:353-361.
46. Mineo D, Ricordi C, Xu X, et al.: Combined islet and hematopoietic stem cell allotransplantation: a clinical pilot trial to induce chimerism and graft tolerance. Am J Transplant 2008 Apr 29 (Epub ahead of print).
47. Jaeger C, Brendel MD, Hering BJ, et al.: Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997, 46:1907-1910.
48. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
49. Campbell PM, Salam A, Ryan EA, et al.: Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007, 7:1242-1248.
50. Cardani R, Pileggi A, Ricordi C, et al.: Allosensitization of islet allograft recipients. Transplantation 2007, 84:1413-1427.